AFP and Zygomycosis: 30% no AFP (group-1), 36% PSZ–AFP (100% suspension; group-2), 21% PSZ–AFP plus another antifungal (caspofungin, L-AMB, FCZ; group-3), 13% other AFP (caspofungin, L-AMB, FCZ; group-4);9% (61/677) proven/probable IFDs; according to AFP, the cumulative incidence of probable/proven IFDs was 13.8% (group-1), 7.9% (group-2), 5.6% (group-3), and 6.6% (group-4) at day 60;PPCs available for 92/383 patients receiving PSZ: only 21.7% PPCs > 0.7 mg/L;Proven/probable IFDs: 38 IA, 17 invasive candidiasis, 6 invasive mucormycosis.